BMJ

1. WISE J
   Meningitis B: All 15 year olds should be offered vaccine on NHS, say expert advisers.
   BMJ. 2026;394:e100313.
   

   >> Share

   
   
2. TAYLOR L
   Gonorrhoea vaccine: Australian study suggests England's "world first" rollout may not work.
   BMJ. 2026;394:e100281.
   

   >> Share

   
   
3. WISE J
   Ebola vaccine: Oxford starts UK trial against Bundibugyo strain.
   BMJ. 2026;394:e100286.
   

   >> Share

   
   

   
   Clin Infect Dis

4. IDRISS J, Kalash S, Faraj JA, Nolan L, et al
   Artificial Intelligence Across the Vaccine Clinical Trial Lifecycle: Evidence, Readiness, and Guardrails.
   Clin Infect Dis. 2026 Jul 17:ciag445. doi: 10.1093.
   

   >> Share

   
   
5. CHUNG JR, Price AM, House SL, Mills J, et al
   Influenza vaccine effectiveness against outpatient acute respiratory illness with laboratory-confirmed influenza, United States, 2024-25 season.
   Clin Infect Dis. 2026 Jul 14:ciag437. doi: 10.1093.
   

   >> Share

   
   
6. PAYNE DC, Weinberg GA, Halasa NB, Englund JA, et al
   The New Vaccine Surveillance Network: 25 years of active, population-based surveillance for pediatric infectious diseases in the United States.
   Clin Infect Dis. 2026 Jul 13:ciag434. doi: 10.1093.
   

   >> Share

   
   
7. HUANG YS, Sun HY, Lin KY, Huang SH, et al
   Birth in the neonatal HBV vaccination era and hepatitis B surface antigen seroclearance in people with HIV and HBV coinfection on tenofovir-containing antiretroviral therapy.
   Clin Infect Dis. 2026 Jul 11:ciag429. doi: 10.1093.
   

   >> Share

   
   

   
   Clin Microbiol Rev

8. PALANISAMY B, Faisal SM
   Leptospira-host interactions: advancing next-generation vaccines and diagnostics.
   Clin Microbiol Rev. 2026 Jul 16:e0037325. doi: 10.1128/cmr.00373.
   

   >> Share

   
   

   
   Infect Immun

9. LIM PS, Bernal J, Karunarathne J, Longley RJ, et al
   Malaria serology for surveillance, insights into immunity, and vaccine development.
   Infect Immun. 2026 Jul 13:e0003126. doi: 10.1128/iai.00031.
   

   >> Share

   
   
10. KUMARESAN V, Smith TC 2nd, Lumbreras M, MacMackin Ingle T, et al
    Protective efficacy of mutant strains of Borrelia burgdorferi as potential reservoir host-targeted biologics against Lyme disease.
    Infect Immun. 2026;94:e0021026.
    

    >> Share

    
    

    
    J Immunol

11. BATTISTONE B, Ghazaryan A, Tang WW, Agir ZB, et al
    T-cell miR-155 regulates the response to tumor-specific mRNA vaccines in a murine model of acute myeloid leukemia.
    J Immunol. 2026;215:vkag184.
    

    >> Share

    
    

    
    J Infect Dis

12. KAWAI N, Bando T, Kawashima T, Matsuura S, et al
    Influenza Attack Rates and Vaccine Effectiveness by Prior-Season Infection and Vaccination: A 17-Season Analysis.
    J Infect Dis. 2026 Jul 11:jiag352. doi: 10.1093.
    

    >> Share

    
    
13. PENG Q, Wong YC, Cheng WY, He Y, et al
    Safety and Immunogenicity of a PD-1-Enhanced HIV-1 Therapeutic DNA Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Trial in People With HIV-1 on Antiretroviral Therapy.
    J Infect Dis. 2026 Jul 14:jiag320. doi: 10.1093.
    

    >> Share

    
    
14. RATU A, Rabukawaqa I, McGregor R, Sassen J, et al
    Neutralisation capacity against SARS-CoV-2 ancestral, Delta and Omicron variants before and after heterologous booster vaccination in Fijian health system workers.
    J Infect Dis. 2026 Jul 17:jiag363. doi: 10.1093.
    

    >> Share

    
    

    
    N Engl J Med

15. SULLIVAN NJ
    Bundibugyo Virus Disease in 2026 - Clinical and Public Health Responses.
    N Engl J Med. 2026;395:278-289.
    

    >> Share

    
    

    
    Nat Med

16. O'LEARY K
    Mining antigens for a universal malaria vaccine.
    Nat Med. 2026 Jul 16. doi: 10.1038/d41591-026-00036.
    

    >> Share

    
    

    
    Pediatr Infect Dis J

17. MADAENG T, Soponkanaporn S, Tangnararatchakit K, Apiwattanakul N, et al
    Immunogenicity of Hepatitis B Vaccine in Pediatric Systemic Lupus Erythematosus Patients: ERRATUM.
    Pediatr Infect Dis J. 2026 Jul 17. doi: 10.1097/INF.0000000000005322.
    

    >> Share

    
    

    
    PLoS Med

18. KUMAR CK, Lo NC
    Re-emergence of vaccine-preventable diseases in the post-elimination era.
    PLoS Med. 2026;23:e1005175.
    

    >> Share

    
    

    
    PLoS One

19. KAYUMBA K, Duga A, Papa Fallah M, Tshidibi C, et al
    Adverse events following immunization during COVID-19 mass vaccination campaigns in the Democratic Republic of Congo: Findings from active safety surveillance.
    PLoS One. 2026;21:e0309628.
    

    >> Share

    
    
20. PEREZ MOLINA CJ, Chavarro Bermeo FE, Perez Hernandez AMB
    Immunoprevention and immunomodulation of yellow fever: A scoping review of global and Latin American evidence.
    PLoS One. 2026;21:e0352755.
    

    >> Share

    
    
21. ABOUSENNA MS, Shafik NG, El Sawy SEA, Mohamed AAEM, et al
    Comprehensive evaluation of an emergency monovalent SAT1 foot-and-mouth-disease vaccine: Antigen quality, product consistency, and protective efficacy.
    PLoS One. 2026;21:e0353701.
    

    >> Share

    
    
22. LEE S, Choi S, Park J, Xuan B, et al
    Postbiotic effects of Enterococcus faecium JB00008 on gut health and IBD vaccination in broiler chickens.
    PLoS One. 2026;21:e0353974.
    

    >> Share

    
    
23. CHEN B, Wang R, Zhao Y, Qian Y, et al
    Construction of MUC2 promoter-type periodontitis DNA vaccine candidate plasmid and preliminary exploration of the effect of Lactobacillus rhamnosus on its expression.
    PLoS One. 2026;21:e0353062.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

24. PAN Q, Zhang C, Wang X, Yin J, et al
    IVT-free, chemically synthesized protein-encoding RNA oligonucleotides for rapid production of personalized cancer vaccines.
    Proc Natl Acad Sci U S A. 2026;123:e2529799123.
    

    >> Share

    
    

    
    Vaccine

25. VELINENI S, Wappel S, Sobell N, King V, et al
    Efficacy and safety of a non-adjuvanted Bordetella bronchiseptica extract vaccine with recombinant pertactin administered subcutaneously to dogs.
    Vaccine. 2026;88:128941.
    

    >> Share

    
    
26. YIH WK, Duffy J, Daley MF, Fireman B, et al
    Using tree-based scan statistics to assess vaccines for possible associations with Guillain-Barre syndrome in the Vaccine Safety Datalink.
    Vaccine. 2026;88:128949.
    

    >> Share

    
    
27. GROOTENDORST A, Paludan-Muller AS, Madsen K, Stovring H, et al
    Expanding enhanced influenza vaccines programs for adults aged >/=65 in the Nordic region predicted to improve public health and health system resilience.
    Vaccine. 2026;88:128934.
    

    >> Share

    
    
28. GYAMFI-SAMAKOME A, Nimo FA, Odoom E, Nabe B, et al
    Impact of health education intervention on knowledge and attitude towards HPV vaccination in Africa: A systematic review.
    Vaccine. 2026;88:128930.
    

    >> Share

    
    
29. SAITOH A, Takaku M
    Partner awareness and support for maternal RSV vaccination: a paired survey of pregnant women and co-residing partners in Japan.
    Vaccine. 2026;88:128946.
    

    >> Share

    
    
30. GUHA R, Wangkahart E, Elumalai P
    Protective immunity of lectin-adjuvanted intraperitoneal injection vaccine against Aeromonas veronii infection in Oreochromis niloticus.
    Vaccine. 2026;88:128948.
    

    >> Share

    
    
31. GEIGER M, Korn L, Temme H, Betsch C, et al
    Cholera vaccination readiness in six African countries: A psychological and ecological study.
    Vaccine. 2026;88:128932.
    

    >> Share

    
    
32. HENSLEY AA, Jiles KA, Edwards S, Clinchard C, et al
    Characteristics of successful and unsuccessful strategies to increase vaccine intention and improve vaccine uptake for U.S. adult populations in the Affordable Care Act era (2010-2025): a systematic review and meta-regression.
    Vaccine. 2026;88:128910.
    

    >> Share

    
    
33. AUNG TN, Muyindike W, Hoeppner SS, Nanfuka V, et al
    COVID-19 vaccination among people with HIV in Uganda: lessons from a high-risk group with high vaccine uptake for the next pandemic.
    Vaccine. 2026;88:128912.
    

    >> Share

    
    
34. CHEN Y, Su Y, Tang X, Pan F, et al
    Comparative immunogenicity of three meningococcal vaccines as the first booster dose in children primed with MPCV-AC in China.
    Vaccine. 2026;88:128916.
    

    >> Share

    
    
35. DE WEERDT L, Boisnard F, Maertens K
    Antibody persistence following primary and toddler booster vaccination of a hexavalent DTaP-IPV-HB-PRP approximately T vaccine and immunogenicity of a school-age aP-containing booster vaccine in term and preterm infants born to women vaccinated with T
    Vaccine. 2026;88:128915.
    

    >> Share

    
    
36. GAYEN M, Gupta P, Morazzani EM, Gaidamakova EK, et al
    Corrigendum to "Deinococcus Mn(2+)-peptide complex: A novel approach to alphavirus vaccine development" [Vaccine 35(29) (2017) 3672-3681].
    Vaccine. 2026;89:128880.
    

    >> Share

    
    
37. MOSS B, Cotter CA, Americo JL, Ignacio MA, et al
    Vaccinia virus and Monkeypox virus neutralizing and antigen-binding antibodies following subcutaneous and reduced intradermal doses of an MVA vaccine.
    Vaccine. 2026;88:128920.
    

    >> Share

    
    
38. WROBLEWSKI M, Mendes PT
    Political ideology, science literacy and future-oriented vaccine optimism in the European Union: a cross-national eurobarometer analysis.
    Vaccine. 2026;88:128926.
    

    >> Share

    
    
39. TYAGI B, Toppo L, Biradar A
    Comment on "Effect of pneumococcal conjugate vaccine booster dose on prevention of invasive pneumococcal disease in British Columbia, 2003-2018".
    Vaccine. 2026;88:128925.
    

    >> Share

    
    
40. KHALED N, Gaghan C, Fares AM, Goodell C, et al
    Herpesvirus of Turkeys (HVT) vaccine confers limited protection against the cellular changes induced by very virulent plus Marek's disease virus (vv + MDV) strains in commercial meat-type chickens.
    Vaccine. 2026;88:128921.
    

    >> Share

    
    
41. HWANG Y, Cakpo GE, Rakotozandrindrainy N, Nana LRW, et al
    Cost-effectiveness analysis of a hypothetical vaccine for schistosomiasis in Madagascar and Burkina Faso.
    Vaccine. 2026;88:128936.
    

    >> Share

    
    
42. CODI A, Rogawski McQuade E, Benkeser D
    Estimating the impact of Shigella vaccines on growth outcomes and implications for clinical trial design.
    Vaccine. 2026;88:128908.
    

    >> Share

    
    
43. SCARIA PV, Chen B, Muratova O, Kemanli P, et al
    Impact of antigen and carrier substitution on the molecular weight and immunogenicity of the Pfs230D1-CRM197 malaria transmission-blocking vaccine.
    Vaccine. 2026;88:128913.
    

    >> Share

    
    
44. JING Y, Chang X, Jin Z, Yang F, et al
    Immunogenicity and safety of serum-free rabies vaccine for human use with simulated post-exposure schedules: A randomized, double-blind, active-controlled phase III clinical trial.
    Vaccine. 2026;88:128914.
    

    >> Share

    
    
45. LADOMENOU F, Matalliotakis M
    Maternal RSV vaccination: A stress test for antenatal care systems.
    Vaccine. 2026;88:128945.
    

    >> Share

    
    
46. HE Q, Pang B, Su Z, Mo Y, et al
    Economic evaluation of alternative PCV13 vaccination strategies in Guangxi, China: a decision tree-Markov model study.
    Vaccine. 2026;88:128935.
    

    >> Share

    
    
47. LI Y, Li Y, Li Y, Jiang W, et al
    Identifying influencing factors and intervention targets for intention strength in tetanus booster vaccination: A cross-sectional study among Chinese adults.
    Vaccine. 2026;88:128942.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share